Carregant...

Single oral dose acute and subacute toxicity of a c-MET tyrosine kinase inhibitor and CDK 4/6 inhibitor combination drug therapy

c-MET inhibitor, crizotinib, and CDK 4/6 inhibitor, palbociclib, have been evaluated in combination as cancer treatment in vitro. Because the toxicological data for the combination of these drugs is limited, we investigated the toxicity of the crizotinib and palbociclib combination in 80 ICR (CD-1)...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Am J Cancer Res
Autors principals: Smith, Brian, Hsu, Yi-Hsin, Flores, Rene, Gagea, Mihai, Craig, Suzanne, Hung, Mien-Chie
Format: Artigo
Idioma:Inglês
Publicat: e-Century Publishing Corporation 2018
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5794732/
https://ncbi.nlm.nih.gov/pubmed/29416931
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!